Loading
Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma.
Anna Nowak (University of Western Australia) led the DREAM phase 2 trial, the first to show durvalumab can be combined with first-line platinum-pemetrexed in mesothelioma, and is co-principal investigator of the international DREAM3R phase 3 trial with PrE0506. Her laboratory work on chemotherapy-induced immune modulation underpins the chemo-immunotherapy approach in the disease.
| Title | Journal | Year |
|---|---|---|
| Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in | Lancet Oncology | 2020 |
| Chemotherapy with or without durvalumab in mesothelioma (DREAM3R): rationale and design | Clinical Lung Cancer | 2021 |
Shares Mesothelioma, Immune checkpoint inhibitors and the tags mesothelioma, immunotherapy.
Shares Mesothelioma, Immune checkpoint inhibitors and the tags mesothelioma, immunotherapy.
Shares the tags mesothelioma, immunotherapy.
Shares Durvalumab, PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.